

4015

Governance: D

JAMJOOM PHARMA

Jamjoom Pharmaceuticals Factory Co.

153.40 SAR / Share

As of: May 28, 2026

<p>23.2x</p> <p>P/E RATIO</p> <p>Trailing 12 Months</p>	<p>6.3x</p> <p>P/B RATIO</p> <p>Price to Book Value</p>	<p>2.3%</p> <p>DIVIDEND YIELD</p> <p>Annual Dividend / Share</p>	<p>10.74B</p> <p>SAR</p> <p>MARKET CAP</p> <p>Total Valuation</p>	<p>0.85</p> <p>BETA</p> <p>Systematic Risk Index</p>	<p>30.9%</p> <p>NET MARGIN</p> <p>Net Profit / Revenue</p>
--	--	---	--	---	---

Company Profile

Jamjoom Pharmaceuticals Factory Company is a Saudi Joint Stock Company involved in the production of human medicines, nutraceuticals, antibiotics, and treatments for various conditions including asthma, heart diseases, and cancer. The Group operates manufacturing facilities in Saudi Arabia and Egypt, with a joint venture in Algeria. Revenue is primarily generated from the sale of pharmaceutical and consumer health products across the KSA, Gulf, Iraq, Egypt, and North Africa.

The Story

"A high-margin pharmaceutical leader in the MENA region demonstrating consistent double-digit revenue growth and robust capital returns."

Financial Metric	Value
Return on Capital (ROIC)	20.2%
Debt-to-Equity Ratio	1.2%
Sustainable Growth Rate	+6.0%

Growth Story

Revenue has grown from 1.10 billion SAR in fiscal 2023 to 1.50 billion SAR for the twelve months ended December 31, 2025, representing a steady upward trajectory. The company's growth is fueled by its expansion in Saudi Arabia, which accounts for 988.7 million SAR of revenue, and key export markets like Iraq and the... [\[Read full story\]](#)

Corporate Governance Profile

Rating: D

We track 8 key governance disclosures in our database.

Profitability Dynamics

Jamjoom Pharma exhibits strong value creation, evidenced by a significant ROIC vs. The operating margin remains healthy at 31.6% for the TTM period, supported by a gross profit of 938.8 million SAR. The company is highly cash-generative, ending 2025 with a cash balance of 357.6 million SAR, even after distributing... [\[Read full story\]](#)

Risk & Capital Structure Factors

The company maintains a conservative risk profile with a net cash position, as its 357.6 million SAR in cash significantly exceeds its total debt of 123.9 million SAR. However, business-specific risks include a high customer concentration, with two major customers accounting for 65.8% of total revenue. Additionally,... [\[Read full story\]](#)